APLS FY 2022 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+13.3% YoY

Gross Profit

$70M92.5% margin

Operating Income

-$595M-788.4% margin

Net Income

-$652M-864.7% margin

EPS (Diluted)

$-6.15

Cash Flow

Operating Cash Flow

-$514M

Free Cash Flow

-$515M

Stock-Based Comp.

$91M

Balance Sheet

Total Assets

$760M

Total Liabilities

$590M

Stockholders' Equity

$170M

Cash & Equivalents

$552M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$67M	+13.3%
Gross Profit	$70M	$61M	+13.7%
Operating Income	-$595M	-$536M	-10.9%
Net Income	-$652M	-$746M	+12.6%